Janssen/Legend’s Cilta-Cel Responses Could Make Up For Second-To-Market Position
Mitigation Strategy Lessens Neurotoxicity Of CAR-T In Myeloma
Cilta-cel likely will be the second BCMA-targeting CAR-T therapy approved in the US for multiple myeloma, but appears to have an efficacy advantage over BMS/bluebird’s first-to-market Abecma.
You may also be interested in...
The European Medicines Agency has added 13 new drugs to its list of products that are under review for potential pan-EU marketing approval.
The launch of efgartigimod at the end of 2021 is very much Argenx's focus now that J&J is terminating their alliance for the anti-CD70 antibody cusatuzumab for acute myeloid leukemia "in consideration of the evolving standard of care" for the disease.
Idecabtagene vicleucel for fifth-line multiple myeloma lags GSK’s BCMA-targeting ADC Blenrep, but it is months ahead of J&J/Legend’s CAR-T. Abecma is BMS’s second CAR-T approval this year.